Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06343805
Title A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ajax Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Cancer Center Tampa Florida 33612 United States Details
University of Kansas Medical Center Kansas City Kansas 66160 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
David H. Koch Center for Cancer Care at Memorial Sloan Kettering New York New York 10021 United States Details
Icahn School of Medicine at Mount Sinai New York New York 10029 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
University of Cincinnati Cincinnati Ohio 45221 United States Details
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field